Parmodulin 2

Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC50 of 0.26 μM[1]. Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo[2].

Product Specifications

CAS Number

[423735-93-7]

Product Name Alternative

ML161

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Protease Activated Receptor (PAR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/parmodulin-2.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC(NC(CCC)=O)=C1)C2=CC=CC=C2Br

Molecular Formula

C17H17BrN2O2

Molecular Weight

361.23

Precautions

H302, H315, H319, H335

References & Citations

[1]Gandhi DM, et al. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorg Med Chem. 2018 May 15;26 (9) :2514-2529.|[2]Susanna F Gunnink, et al. Allosteric inhibition of protease activated receptor 1: a new antiplatelet therapy.|[3]Aisiku O, et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood. 2015 Mar 19;125 (12) :1976-85.